NCT03430687View on ClinicalTrials.gov

Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 1, 2018

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2020

Conditions
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Talimogene Laherparepvec

Given intravesically

Trial Locations (1)

94115

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

University of California, San Francisco

OTHER